Skip to main content

Table 2 Relationship of baseline (start of infusion) values to 28-day mortality in PROWESS placebo patients

From: Protein C: a potential biomarker in severe sepsis and a possible tool for monitoring treatment with drotrecogin alfa (activated)

Baseline measure Cut-offa Number of patients at increased risk using cut-off (n [%]) Odds ratio (95% CI) AUCb
Protein C (%) <40 243 (31.4%) 2.12 (1.55–2.89) 58.9%
Protein S (%) <46 239 (31.5%) 1.91 (1.38–2.64) 57.7%
Antithrombin III (%) <53 240 (31.4%) 2.32 (1.70–3.18) 60.1%
interleukin-6 (pg/ml) ≥704.6 252 (31.2%) 2.21 (1.63–2.99) 59.7%
Prothrombin time (seconds) ≥18.4 240 (31.5%) 1.89 (1.38–2.58) 57.4%
D-dimer (μg/ml) ≥4.45 241 (31.8%) 1.51 (1.11–2.05) 55.1%
Cardiovascular SOFA ≥4 259 (30.8%) 1.63 (1.21–2.18) 56.0%
Respiratory SOFA ≥4 257 (31.2%) 1.76 (1.27–2.44) 55.5%
Renal SOFA ≥1 258 (30.8%) 2.14 (1.55–2.95) 58.6%
Hematologic SOFA ≥2 259 (30.8%) 1.69 (1.20–2.38) 54.6%
Hepatic SOFA ≥2 239 (31.3%) 1.31 (0.89–1.93) 52.1%
  1. aCut-off based on maximum sensitivity and specificity when both were ≥ 40% for predicting 28-day mortality. Using a cut-off for each measure allowed comparison of odds ratios and treatment interactions on a consistent binary scale across variables. bArea under the receiver operating characteristic curve (AUC) based on 28-day mortality outcome in logistic regression models with the cut-off as the univariate independent variable; this is a combined measure of sensitivity and specificity. CI, confidence interal; PROWESS, Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis; SOFA, Sequential Organ Failure Assessment.